ISIS was hit hard on on concerns with their lead antisense drug which is the same basic chemistry as OGXI drugs but a different target. This hurt OGXI two ways. One is there are a lot of shareholders that own both so with ISIS getting killed it puts some pressure on OGXI. More significant is the weak panel approval for ISIS' drug included concerns about that basic antisense oligonucleotide chemistry itself. I think some concerns are warranted with the ISIS drug but for cancer and IV infusion they should be OK. One of the ISIS mipomersen concerns was about potentially more cancers. It's questionable whether there's anything there but again none of this should affect the OGXI drugs where you're talking about short term use in patients with cancer. The ISIS drug is meant to be taken for life.